AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
. Carbonyl groups are common to many classes of organic compounds and are also a part of many larger functional groups. 2. An inorganic or organometallic coordination complex with carbon monoxide as a ligand (e.g. a metal carbonyl).
=== As an antibiotic target === The sortases are thought to be good targets for new antibiotics as they are important proteins for pathogenic bacteria and some limited commercial interest has been noted by at least one company.
For example, because of this trend in the sizes of orbitals, a large difference in atomic radii between the first and second members of each main group is seen in groups 1 and 13–17: it exists between neon and argon, and between helium and beryllium, but not between helium and neon. This similarly affects the noble gases' boiling points and solubilities in water, where helium is too close to neon, and the large difference characteristic between the first two elements of a group appears only between neon and argon. Moving helium to group 2 makes this trend consistent in groups 2 and 18 as well, by making helium the first group 2 element and neon the first group 18 element: both exhibit the characteristic properties of a kainosymmetric first element of a group. The group 18 placement of helium nonetheless remains near-universal due to its extreme inertness. Additionally, tables that float both hydrogen and helium outside all groups may rarely be encountered.
Sources: en.wikipedia.org
Synthesis during the formation of the universe is the only significant way naturally occurring deuterium has been created; it is destroyed in stellar fusion. Deuterium is thought to have played an important role in setting the number and ratios of the elements that were formed in the Big Bang. Combining thermodynamics and the changes brought about by cosmic expansion, one can calculate the fraction of protons and neutrons based on the temperature at the point that the universe cooled enough to allow formation of nuclei. This calculation indicates seven protons for every neutron at the beginning of nucleogenesis, a ratio that would remain stable even after nucleogenesis was over. This fraction was in favor of protons initially, primarily because the lower mass of the proton favored their production. As the Universe expanded, it cooled. Free neutrons and protons are less stable than helium nuclei, and the protons and neutrons had a strong energetic reason to form helium-4. However, forming helium-4 requires the intermediate step of forming deuterium. Through much of the few minutes after the Big Bang during which nucleosynthesis could have occurred, the temperature was high enough that the mean energy per particle was greater than the binding energy of weakly bound deuterium; therefore, any deuterium that was formed was immediately destroyed. This situation is known as the deuterium bottleneck. The bottleneck delayed formation of any helium-4 until the Universe became cool enough to form deuterium (at about a temperature equivalent to 100 keV).
Congebec Logistics is a Quebec City, Quebec based company that provides cold and multi-temperature storage, warehousing and distribution services. It is the second largest refrigerated logistics services provider in Canada. Congebec is considered the 11th largest refrigerated storage company in North America and 18th largest in the world by the International Association of Refrigerated Warehouses (IARW). The company has twelve temperature-controlled facilities across Canada in Boucherville, Sainte-Julie, Montreal, Quebec City, Toronto, Winnipeg, Saskatoon and Calgary with a total of 49,66 million cubic feet (1,406,212) m3) of refrigerated and frozen space. In addition to offering multi-temperature storage and packing services, Congebec also offer logistics and transportation services to its customers.
As of 2016, NASA has published over 2,000 other spin-offs in the fields of computer technology, environment and agriculture, health and medicine, public safety, transportation, recreation, and industrial productivity. Contrary to common belief, NASA did not invent Tang, Velcro or Teflon.
United States Policies targeting Muslims: Since the implementation of added security measures in the aftermath of the 2001 World Trade Centre attacks, reports of discrimination against people perceived to be Muslim by American border security officers have been prevalent in the media. The travel restrictions implemented during the Trump presidency primarily against Muslim majority countries have provoked controversy over whether such measures are a legitimate Border security measure or unethically discriminatory. Separation of families seeking asylum: In April 2018, as part of its "zero tolerance" policy, the American government ordered the separation of the children of refugees and asylum seekers from their parents. As a consequence of popular outrage, and criticism from the medical and religious communities, the policy was put on hold by an executive order signed by Trump on 20 June 2018. Under the policy, federal authorities separated children from their parents, relatives, or other adults who accompanied them in crossing the border, whether apprehended during an illegal crossing or, in numerous reported cases, legally presenting themselves for asylum. The policy involved prosecuting all adults detained at the Mexican border, imprisoning parents, and handing minors to the American Department of Health and Human Services (Spanish: Departamento de Salud y Servicios Sociales de los Estados Unidos). The federal government reported that the policy resulted in the separation of over 2300 children from their parents.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.